Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pirker

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2012
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX studyR Pirker, J R Pereira, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerR Rosell, G Robinet, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2012
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX studyR Pirker, J R Pereira, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerR Rosell, G Robinet, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Pageof 8